Knight Therapeutics Announces Submission to B3 S.A. For Unified Tender Offer
MONTREAL, Dec. 20, 2019 — Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. (“Knight” or “Offeror“) today announced that, further to its acquisition of a controlling interest (the “Transfer of Control“) in Biotoscana Investments S.A. (“GBT” or “Company“), it has submitted to B3 S.A. – Brasil, Bolsa, Balcão (“B3”) the […]
Knight Therapeutics Announces Closing of Previously Announced Acquisition of Grupo Biotoscana
Transformational acquisition establishes Knight as a premiere pan-American (ex-US) specialty pharma company MONTREAL, Nov. 29, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) today announced that it has completed the acquisition of a 51.2% interest in Biotoscana Investments S.A. (B3: GBIO33) (“GBT” or “Grupo Biotoscana”) from a controlling shareholder group that includes Advent International and […]
Knight and TherapeuticsMD Announce Filing of New Drug Submission for Bijuva® in Canada
MONTREAL and BOCA RATON, Fla., Nov. 26, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Bijuva® has been accepted for review by Health Canada. Bijuva is a bio-identical* hormone therapy combination of estradiol and progesterone in a single, daily oral capsule intended […]
GUD Medison Resolved
MONTREAL and PETACH TIKVA, Israel, Nov. 21, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“) and Medison Biotech (1995) Ltd. (“Medison“) announced today that they have agreed to separate their businesses and allow each of the companies to focus on growing their respective businesses independently. Knight and Medison have entered into a definitive agreement pursuant […]
Knight Therapeutics Reports Third Quarter 2019 Results
MONTREAL, Nov. 12, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2019. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3 2019 Highlights Financials Revenues were $4,030, […]
Notice of Knight Therapeutics' Third Quarter 2019 Results Conference Call
MONTREAL, Nov. 05, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2019 financial results on Tuesday, November 12, 2019 after market closing. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this […]
Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada
MONTREAL and BOCA RATON, Fla., Oct. 30, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms […]
Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada
MONTREAL, Oct. 23, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and SIFI S.p.A. (“SIFI”), a prominent Italian Eye Care company, today announced that Health Canada has approved NETILDEX® for the treatment of inflammatory ocular conditions of the anterior segment of the eye following cataract surgery where adjunct topical […]
Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform
Transformational acquisition establishes Knight as a premiere pan-American (ex-US) specialty pharma company Executes on Knight’s strategy to build a Rest of World specialty pharmaceutical company and become the partner of choice for top pharmaceutical companies for pan-American (ex-US) in-licensing opportunities Strong regional infrastructure and management team with a unique footprint across 10 countries in Latin […]
Knight Therapeutics Reports Second Quarter 2019 Results
MONTREAL, Aug. 08, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2019. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2 2019 Highlights Financials Revenues were $3,204, […]
